TargetBeta
ADAMTS13
ADAM metallopeptidase with thrombospondin type 1 motif 13 · also VWFCP, TTP, vWF-CP, FLJ42993 · ADAM metallopeptidases with thrombospondin type 1 motif
1 program in company-led studies act on ADAMTS13, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| apadamtase alfarule | Takeda | phase 3 | 72 running | – | NCIt |
Conditions their studies are in
- Anemia, Sickle Cell, 1 program
- Ischemic Stroke, 1 program
- Purpura, Thrombotic Thrombocytopenic, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 16, 2027apadamtase alfa · Takeda · phase 3 · NCT04683003
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.